AUPH — Aurinia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.84bn
- $283.06m
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death
Canada's Aurinia Pharmaceuticals Q1 revenue rises 24% on LUPKYNIS demand
Kezar gains on Aurinia buyout deal
Brief: Aurinia Pharmaceuticals To Acquire Kezar Life Sciences For $6.955 In Cash Per Share Plus A Contingent Value Right
Brief: Aurinia Announces Management Transition
Canada's Aurinia Pharma Q4 revenue jumps on LUPKYNIS demand
Brief: Aurinia Pharmaceuticals To Report Financial Results For The Three And Twelve Months Ended December 31, 2025
Aurinia Pharmaceuticals Q3 profit doubles on strong LUPKYNIS sales, raises FY sales view
US FDA's drug division chief resigns amid ethics concerns and lawsuit
Brief: Aurinia Pharmaceuticals To Report Q3 Results, Provide Update On Recent Business Progress On November 4
Press Digest: Wall Street Journal - November 3
Brief: Aurinia to Present New LUPKYNIS® Data at ACR Convergence and ASN Kidney Week 2025
Aurinia Pharma rises after defending lupus drug
Aurinia Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Aurinia Pharmaceuticals Q2 revenue up 22%, raises guidance
Aurinia Pharmaceuticals Inc expected to post earnings of 14 cents a share - Earnings Preview